Drug Discovery

Medical research
#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

ADME and DDI considerations during drug development

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

#Drug development #Drug discovery #Generics #Regulatory

Pioneering access to complex generic products 

Claire D’Abreu-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines.   Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. This will continue to be the case going forward,… Read More

#Exclusive Content

Medical researcher
#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

ADME and DDI considerations during drug development

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

Lab mouse
#Animal models #Drug discovery #Mouse models #Taconic

More efficient mouse model generation through informed founder selection

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. Yet when seeking to obtain an existing model, researchers often encounter obstacles related to intellectual property, availability, or licensing. Read More

#Exclusive Content

Regulatory concept
#AI / data analytics / healthtech / informatics #Digitalisation #Drug development #Regulatory

Reflections on life science’s regulatory environment  

In this article, Amplexor asks some of the company’s closest industry partners and BE THE EXPERT event speakers for their views on the biggest developments in the Life Sciences Regulatory sphere over the last 12 months – and explore some of the most prominent themes and priorities seen throughout… Read More

#Exclusive Content

Medical research
#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

Learn about ADME and DDI considerations in drug discovery

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

#Business #Drug discovery #Investment #Mergers and acquisitions

Five key drug discovery deals of summer 2023

The life sciences sector has seen significant M&A activity over the last few weeks. DDW’s Diana Spencer provides an overview. BioIVT acquires PrecisionMed In July BioIVT acquired biospecimens company PrecisionMed, gaining access to, reportedly, the largest private, global repository of longitudinally collected human CSF for scientific… Read More

#Business & Investment #Editor's Choice #News

Diversity
#Clinical research #Clinical trials #Diversity #Drug development #Organoids

The importance of introducing diversity earlier in drug development 

DDW’s Reece Armstrong speaks to Shantanu Dhamija, VP of Strategy and Innovation at Molecular Devices about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups.   RA: Why is US clinical trial diversity at its… Read More

#Exclusive Content

Advanced therapies
#Advanced Therapies #CAR-T #Cell and gene therapy #Drug development

Commercialising advanced therapies: Industry perspectives 

Dr Christian K Schneider, Head of Biopharma Excellence at PharmaLex, presents the findings of an industry panel debate on barriers to commercialisation of novel treatments, and the most effective strategies to bring them to market.  With so many exciting novel treatments emerging from the labs, biotechs and pharma companies… Read More

#Exclusive Content #Opinion

Genetic research
#CAR-T #Drug development #Drug discovery #Synthetic biology

Synthetic biology: Innovating in drug discovery

Listen to this article on the DDW Podcast: Synthetic biology is increasingly important to drug discovery and development. Reece Armstrong examines recent activity within the sector and highlights some of the key advancements and innovation. Partnerships Earlier this year cell-engineering company MaxCyte signed… Read More

#Exclusive Content

Heart health concept
#Drug discovery #Heart attack #Regenerative Medicine #Stem cells #Turning Science into Business

Turning Science into Business: Can regenerative medicine treat heart attacks?   

DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.   Based in France, CellProthera is a small, regenerative cell… Read More

#Exclusive Content

Biologics research
#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

Guide: Assessing thermal stability with nanoDSF

A new Guide ‘The biologics researcher’s mini-guide to screening candidates with nanoDSF’ is now available from NanoTemper. Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read More

#News

#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

The biologics researcher’s mini-guide to screening candidates with nanoDSF

Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read this mini-guide to learn: How nanoDSF uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset… Read More

#Intelligence #Resources

Antibodies
#Antibodies #Drug discovery #eBook

eBook: Breakthroughs accelerating therapeutic antibodies

The latest eBook by DDW is out now. This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends… Read More

#News